NEO SEC Filings: 8-K, 10-Q, S-3 & 424B – NeoGenomics

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 28, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 28, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Apr 28, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 17, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 28, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 29, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NeoGenomics Reports Third Quarter 2026 Results and Raises Full-Year Guidance

Oct 28, 2026

8-K

NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan

Oct 5, 2026

8-K

NeoGenomics Announces Departure of EVP, General Counsel & Business Development

Aug 11, 2026

8-K

NeoGenomics Reports Second Quarter 2026 Results and Raises Full-Year Guidance

Jul 28, 2026

8-K/A

Company Amends Report to Correct Date Error, Finalizes $9.8 Million Settlement with DOJ Over Healthcare Compliance Investigation

Jul 22, 2026

8-K

NeoGenomics Finalizes Settlement with DOJ and OIG Regarding Laboratory Collaboration Initiative

Jul 20, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B7

Form 424B7 - Prospectus [Rule 424(b)(7)]

Apr 7, 2021

424B5

This offering is not contingent on the consummation of the Concurrent Common Stock Offering.-

Jan 8, 2021

424B5

4,081,632 Shares-

Jan 8, 2021

424B5

As of May 17, 2019, we had 95,469,780 shares of Common Stock outstanding.-

Jan 5, 2021

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

May 1, 2020

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

May 1, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-8